Acquisition creates a strong community of global technology providers for the clinical research and healthcare software industries.
ROCHESTER, NY. – Bio-Optronics, maker of CCTrialSuite, which includes the leading clinical trial management system (CTMS) Clinical Conductor, Momentum Scheduling and Biopoint patient workflow solutions, is pleased to announce that it has been acquired by Advarra, the market leader in regulatory review solutions, research quality and compliance consulting services and clinical site technologies.
“We’re delighted to be joining Advarra, a company that shares our purpose and values and has complementary products and expertise,” said Dan Kerpelman, CEO of Bio-Optronics. “We look forward to leveraging our combined strengths and broadened customer base to provide connected clinical research and healthcare technology solutions.”
Along with the extensive clinical research technology of Clinical Conductor CTMS, Bio-Optronics will enhance the Advarra portfolio with a number of eClinical solutions designed to decentralize the workflows of clinical research organizations, as well as their Momentum Scheduling and Biopoint healthcare systems that maximize patient access to care and optimize staff and resource allocation.
“The addition of CCTrialSuite and Bio-Optronics’ global customer base enhances Advarra’s technology portfolio and further solidifies our position as the de-facto standard for clinical research site technology,” stated Advarra’s CEO, Gadi Saarony. “Additionally, the acquisition further strengthens our ability to enable sites with technology and services built for their unique needs and connect them to CROs and sponsor organizations in the clinical trial ecosystem to accelerate the advancement of human health.”
The combined organization will provide current and future customers expanded technology offerings designed for all research sites globally including academic medical centers, health systems and hospitals of any size or configuration, site networks and community sites. Bio-Optronics and Advarra continue to strive for a collaborative customer community in order to promote best practices and work together to move research forward.
“This acquisition significantly enhances Bio-Optronics’ already established value as a partner for sites and site networks,” commented Paul Evans, President and CEO of the leading research site organization Velocity. He further added, “The combination of Advarra and Bio-Optronics delivers increased scale, valuable resources, and improved access and opportunity to connect and collaborate with sponsors and CROs.
Bio-Optronics is a leading software and services company dedicated to providing user-focused applications for healthcare organizations that positively impact operational performance and financial results. With applications focused on clinical research, automated resource utilization and patient safety, Bio-Optronics solutions are used by thousands of healthcare organizations worldwide to simplify complex clinical processes, enhance financial performance, ensure regulatory compliance, increase patient safety, boost efficiency, and ensure the overall quality of results.
Advarra advances the way clinical research is conducted: bringing life sciences companies, CROs, research sites, investigators, and academia together at the intersection of safety, technology, and collaboration. With trusted IRB and IBC review solutions, innovative technologies, experienced consultants, and deep-seated connections across the industry, Advarra provides integrated solutions that safeguard trial participants, empower clinical sites, ensure compliance, and optimize research performance. Advarra is advancing clinical trials to make them safer, smarter, and faster. For more information, visit www.advarra.com.